Wnt Signaling in Liver Cancer

Overview

Journal Curr Drug Targets

Publisher Bentham Science Publishers

Specialty Pharmacology

Date 2008 Nov 11

PMID 18991612

Citations 69

Authors

Yutaka Takigawa

Anthony M C Brown

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is a major cause of cancer death worldwide. As in many other types of cancer, aberrant activation of the canonical Wnt/beta-catenin signaling pathway is an important contributor to tumorigenesis. In HCC this frequently occurs through mutations in the N-terminal region of beta-catenin that stabilize the protein and permit an elevated level of constitutive transcriptional activation by beta-catenin/TCF complexes. In this article we review the abundant evidence that Wnt/beta-catenin signaling contributes to liver carcinogenesis. We also discuss what is known about the roles of Wnt signaling in liver development, regeneration, and stem cell behavior, in an effort to understand the mechanisms by which activation of the canonical Wnt pathway promotes tumor formation in this organ. The Wnt/beta-catenin pathway presents itself as an attractive target for developing novel rational therapies for HCC, a disease for which few successful treatment strategies are currently available.

Citing Articles

Tryptophan fuels MYC-dependent liver tumorigenesis through indole 3-pyruvate synthesis.

Venkateswaran N, Garcia R, Lafita-Navarro M, Hao Y, Perez-Castro L, Nogueira P Nat Commun. 2024; 15(1):4266.

PMID: 38769298 PMC: 11106337. DOI: 10.1038/s41467-024-47868-3.

Machine learning and multi-omics data reveal driver gene-based molecular subtypes in hepatocellular carcinoma for precision treatment.

Wang M, Yan X, Dong Y, Li X, Gao B PLoS Comput Biol. 2024; 20(5):e1012113.

PMID: 38728362 PMC: 11230636. DOI: 10.1371/journal.pcbi.1012113.

Overexpression of RBM34 Promotes Tumor Progression and Correlates with Poor Prognosis of Hepatocellular Carcinoma.

Wang W, Zhang R, Feng N, Zhang L, Liu N J Clin Transl Hepatol. 2023; 11(2):369-381.

PMID: 36643033 PMC: 9817046. DOI: 10.14218/JCTH.2022.00166.

Cancer Metastasis and Treatment Resistance: Mechanistic Insights and Therapeutic Targeting of Cancer Stem Cells and the Tumor Microenvironment.

Kilmister E, Koh S, Weth F, Gray C, Tan S Biomedicines. 2022; 10(11).

PMID: 36428556 PMC: 9687343. DOI: 10.3390/biomedicines10112988.

De novo identification of maximally deregulated subnetworks based on multi-omics data with DeRegNet.

Winkler S, Winkler I, Figaschewski M, Tiede T, Nordheim A, Kohlbacher O BMC Bioinformatics. 2022; 23(1):139.

PMID: 35439941 PMC: 9020058. DOI: 10.1186/s12859-022-04670-6.

References

Wirths O, Waha A, Weggen S, Schirmacher P, Kuhne T, Goodyer C . Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms' tumors. Lab Invest. 2003; 83(3):429-34. DOI: 10.1097/01.lab.0000059926.66359.bd. View

Xu Q, Wang Y, Dabdoub A, Smallwood P, Williams J, Woods C . Vascular development in the retina and inner ear: control by Norrin and Frizzled-4, a high-affinity ligand-receptor pair. Cell. 2004; 116(6):883-95. DOI: 10.1016/s0092-8674(04)00216-8. View

Cadoret A, Ovejero C, Terris B, Souil E, Levy L, Lamers W . New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene. 2002; 21(54):8293-301. DOI: 10.1038/sj.onc.1206118. View

Benhamouche S, Decaens T, Godard C, Chambrey R, Rickman D, Moinard C . Apc tumor suppressor gene is the "zonation-keeper" of mouse liver. Dev Cell. 2006; 10(6):759-70. DOI: 10.1016/j.devcel.2006.03.015. View

Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T . AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet. 2000; 24(3):245-50. DOI: 10.1038/73448. View

Udatsu Y, Kusafuka T, Kuroda S, Miao J, Okada A . High frequency of beta-catenin mutations in hepatoblastoma. Pediatr Surg Int. 2001; 17(7):508-12. DOI: 10.1007/s003830000576. View

Audard V, Grimber G, Elie C, Radenen B, Audebourg A, Letourneur F . Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations. J Pathol. 2007; 212(3):345-52. DOI: 10.1002/path.2169. View

Burke Z, Tosh D . The Wnt/beta-catenin pathway: master regulator of liver zonation?. Bioessays. 2006; 28(11):1072-7. DOI: 10.1002/bies.20485. View

Kondo Y, Kanai Y, Sakamoto M, Genda T, Mizokami M, Ueda R . Beta-catenin accumulation and mutation of exon 3 of the beta-catenin gene in hepatocellular carcinoma. Jpn J Cancer Res. 2000; 90(12):1301-9. PMC: 5926034. DOI: 10.1111/j.1349-7006.1999.tb00712.x. View

10.

Fujino T, Asaba H, Kang M, Ikeda Y, Sone H, Takada S . Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion. Proc Natl Acad Sci U S A. 2003; 100(1):229-34. PMC: 140935. DOI: 10.1073/pnas.0133792100. View

11.

Devereux T, Anna C, Foley J, White C, Sills R, Barrett J . Mutation of beta-catenin is an early event in chemically induced mouse hepatocellular carcinogenesis. Oncogene. 1999; 18(33):4726-33. DOI: 10.1038/sj.onc.1202858. View

12.

Nhieu J, Renard C, Wei Y, Cherqui D, Zafrani E, Buendia M . Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol. 1999; 155(3):703-10. PMC: 1866892. DOI: 10.1016/s0002-9440(10)65168-1. View

13.

Wang H, Zhang J, Feng W, Zhang S, Liang H, Wang Y . PIN1 gene overexpression and beta-catenin gene mutation/expression in hepatocellular carcinoma and their significance. J Huazhong Univ Sci Technolog Med Sci. 2007; 27(1):54-7. DOI: 10.1007/s11596-007-0116-z. View

14.

Lepourcelet M, Chen Y, France D, Wang H, Crews P, Petersen F . Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell. 2004; 5(1):91-102. DOI: 10.1016/s1535-6108(03)00334-9. View

15.

Clevers H . Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127(3):469-80. DOI: 10.1016/j.cell.2006.10.018. View

16.

Gordon M, Nusse R . Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem. 2006; 281(32):22429-33. DOI: 10.1074/jbc.R600015200. View

17.

Moon R, Kohn A, De Ferrari G, Kaykas A . WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet. 2004; 5(9):691-701. DOI: 10.1038/nrg1427. View

18.

Harada N, Miyoshi H, Murai N, Oshima H, Tamai Y, Oshima M . Lack of tumorigenesis in the mouse liver after adenovirus-mediated expression of a dominant stable mutant of beta-catenin. Cancer Res. 2002; 62(7):1971-7. View

19.

Apte U, Zeng G, Thompson M, Muller P, Micsenyi A, Cieply B . beta-Catenin is critical for early postnatal liver growth. Am J Physiol Gastrointest Liver Physiol. 2007; 292(6):G1578-85. DOI: 10.1152/ajpgi.00359.2006. View

20.

Tokumoto N, Ikeda S, Ishizaki Y, Kurihara T, Ozaki S, Iseki M . Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas. Int J Oncol. 2005; 27(4):973-80. View